ES2136673T3 - Utilizacion del factor de crecimiento de los queratinocitos para la obtencion de medicamentos. - Google Patents

Utilizacion del factor de crecimiento de los queratinocitos para la obtencion de medicamentos.

Info

Publication number
ES2136673T3
ES2136673T3 ES94104804T ES94104804T ES2136673T3 ES 2136673 T3 ES2136673 T3 ES 2136673T3 ES 94104804 T ES94104804 T ES 94104804T ES 94104804 T ES94104804 T ES 94104804T ES 2136673 T3 ES2136673 T3 ES 2136673T3
Authority
ES
Spain
Prior art keywords
keratinocit
medicines
obtaining
growth factor
kgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94104804T
Other languages
English (en)
Inventor
Glenn F Pierce
Regina M Housley
Charles F Morris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21912689&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2136673(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ES2136673T3 publication Critical patent/ES2136673T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cosmetics (AREA)

Abstract

BASADOS EN EXTENSOS ESTUDIOS EN VIVO EN ANIMALES, SE HA DESCUBIERTO AHORA QUE EL KGF ESTIMULA LA PROLIFERACION, CRECIMIENTO Y DIFERENCIACION EN VARIAS CELULAS DE TEJIDO EPITELIAL, CERCA DE LOS QUERATINOCITOS. ESTE MEJOR ENTENDIMIENTO DE LOS EFECTOS BIOLOGICOS DEL KGF EN VIVO, PERMITE EL EMPLEO DE ESTE POLIPEPTIDO COMO UN AGENTE TERAPEUTICO, ADECUADAMENTE FORMULADO EN UNA COMPOSICION FARMACEUTICA, PARA EL TRATAMIENTO ESPECIFICO DE ESTADOS DE ENFERMEDAD Y CONDICIONES MEDICAS QUE AFECTAN A LOS TEJIDOS Y A ORGANOS TALES COMO LA ADNEXAE DERMICA, EL HIGADO, EL PULMON, Y EL TRACTO GASTROINTESTINAL.
ES94104804T 1993-03-26 1994-03-25 Utilizacion del factor de crecimiento de los queratinocitos para la obtencion de medicamentos. Expired - Lifetime ES2136673T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4074293A 1993-03-26 1993-03-26

Publications (1)

Publication Number Publication Date
ES2136673T3 true ES2136673T3 (es) 1999-12-01

Family

ID=21912689

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94104804T Expired - Lifetime ES2136673T3 (es) 1993-03-26 1994-03-25 Utilizacion del factor de crecimiento de los queratinocitos para la obtencion de medicamentos.

Country Status (23)

Country Link
EP (1) EP0619370B1 (es)
JP (1) JP3578761B2 (es)
KR (1) KR100390340B1 (es)
CN (1) CN1064710C (es)
AT (1) ATE183233T1 (es)
AU (1) AU707340B2 (es)
CA (1) CA2159109C (es)
CZ (1) CZ285996B6 (es)
DE (1) DE69419958T2 (es)
DK (1) DK0619370T3 (es)
ES (1) ES2136673T3 (es)
FI (1) FI954541A7 (es)
GR (1) GR3031509T3 (es)
HU (1) HU220641B1 (es)
IL (4) IL137581A (es)
NO (1) NO953781L (es)
NZ (1) NZ263967A (es)
RU (1) RU2146148C1 (es)
SG (1) SG49841A1 (es)
SI (1) SI0619370T1 (es)
SK (1) SK281674B6 (es)
UA (1) UA46706C2 (es)
WO (1) WO1994023032A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN271295A0 (en) * 1995-05-02 1995-05-25 Gropep Pty Ltd Method of treatment
DE69530403T2 (de) * 1994-10-13 2003-10-30 Amgen Inc., Thousand Oaks Analogen des keratinozytenwachstumfaktors
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
US6077692A (en) 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
ATE241639T1 (de) * 1995-02-14 2003-06-15 Human Genome Sciences Inc Keratinozyten-wachstumsfaktor 2
EP1486565B1 (en) * 1995-10-11 2007-11-21 Novartis Vaccines and Diagnostics, Inc. Combination of PDGF, KGF, IGF, and IGFBP for wound healing
GB9619660D0 (en) * 1996-09-20 1996-11-06 Scient Hospital Suppl Int Ltd Prevention of gastrointestinal damage
EP1452205B1 (en) * 1996-10-15 2007-11-28 Amgen Inc. Uses of keratinocyte growth factor-2
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
CA2268741C (en) * 1996-10-15 2007-04-24 Amgen Inc. Uses of keratinocyte growth factor-2
US20010006939A1 (en) * 1997-10-03 2001-07-05 Ralph W. Niven Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
US6228839B1 (en) * 1997-12-19 2001-05-08 Emory University Use of keratinocyte growth factor to improve oxidative status
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
WO1999032135A1 (en) 1997-12-22 1999-07-01 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
US6599879B1 (en) 1998-02-13 2003-07-29 Human Genome Sciences, Inc. Therapeutic uses of keratinocyte growth factor-2
US6335317B1 (en) 1998-04-10 2002-01-01 Emory University Use of gut-trophic growth factors to improve oxidative status
MXPA02009176A (es) 2000-03-20 2004-08-12 Pfizer Prod Inc Tratamiento combinado con factor de crecimiento de queratinocito e inhibidor del factor de crecimiento epidermico.
CA2437270A1 (en) * 2001-02-06 2002-08-15 Merck Patent Gesellschaft Mit Beschraenkter Haftung Modified keratinocyte growth factor (kgf) with reduced immunogenicity
US7202066B2 (en) 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
RU2243784C2 (ru) * 2003-02-25 2005-01-10 Козлов Владимир Александрович Способ лечения больных хроническим гепатитом
EP1789138A2 (en) * 2004-09-13 2007-05-30 University Of Southampton Growth factor treatment for asthma
RU2391990C1 (ru) * 2008-11-25 2010-06-20 Александр Сергеевич Ботин Композиция для стимулирования роста и регенерации клеток, (варианты), а также способ ее получения (варианты)
CN101822821B (zh) * 2010-04-27 2013-01-23 复旦大学附属中山医院 角质细胞生长因子-2在制备防治肺损伤的药物中的应用
CN104707164B (zh) * 2015-03-31 2017-01-18 中国人民解放军军事医学科学院基础医学研究所 一种复合壳聚糖水凝胶敷料及其制备方法和应用
CN106226511B (zh) * 2016-07-28 2018-04-06 苏州金盟生物技术有限公司 一种重组人角质细胞生长因子生物学活性检测方法
CN107753932A (zh) * 2016-08-22 2018-03-06 中国辐射防护研究院 Kgf在制备治疗或预防放射性肠炎药物中的用途
JP7135106B2 (ja) 2018-11-27 2022-09-12 株式会社海月研究所 頭皮頭髪用組成物
KR20210114646A (ko) * 2020-03-11 2021-09-24 (주)메디코스바이오텍 성장인자를 함유하는 탈모 치료 또는 모발 성장 촉진용 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2153816T3 (es) * 1989-01-31 2001-03-16 Jeffrey S Rubin Adn que codifica un factor de crecimiento especifico contra celulas epiteliales.
JPH04224522A (ja) * 1990-04-27 1992-08-13 Merck & Co Inc 繊維芽細胞増殖因子含有組成物による禿頭症の治療又は予防方法
FI924778A0 (fi) * 1991-02-22 1992-10-21 Amgen Inc Anvaendning av gm-csf och g-csf foer foersnabbande av saorlaekning

Also Published As

Publication number Publication date
GR3031509T3 (en) 2000-01-31
HUT72711A (en) 1996-05-28
IL137581A (en) 2009-09-01
ATE183233T1 (de) 1999-08-15
SI0619370T1 (en) 1999-10-31
CN1064710C (zh) 2001-04-18
HU9502800D0 (en) 1995-12-28
CZ248295A3 (en) 1996-12-11
JP3578761B2 (ja) 2004-10-20
CA2159109C (en) 2004-11-16
EP0619370B1 (en) 1999-08-11
CA2159109A1 (en) 1994-10-13
UA46706C2 (uk) 2002-06-17
AU6524394A (en) 1994-10-24
SK118595A3 (en) 1996-11-06
EP0619370A1 (en) 1994-10-12
DE69419958D1 (de) 1999-09-16
CZ285996B6 (cs) 1999-12-15
SK281674B6 (sk) 2001-06-11
IL109122A (en) 2004-07-25
KR100390340B1 (ko) 2003-09-26
IL109122A0 (en) 1994-06-24
IL161568A0 (en) 2004-09-27
RU2146148C1 (ru) 2000-03-10
NZ263967A (en) 2005-02-25
AU707340B2 (en) 1999-07-08
JP2002526026A (ja) 2002-08-13
FI954541L (fi) 1995-11-23
WO1994023032A1 (en) 1994-10-13
FI954541A0 (fi) 1995-09-25
DE69419958T2 (de) 2000-04-20
KR960701204A (ko) 1996-02-24
CN1217022A (zh) 1999-05-19
NO953781D0 (no) 1995-09-25
SG49841A1 (en) 1998-06-15
IL137581A0 (en) 2001-07-24
HU220641B1 (hu) 2002-03-28
DK0619370T3 (da) 2000-02-28
NO953781L (no) 1995-11-27
FI954541A7 (fi) 1995-11-23

Similar Documents

Publication Publication Date Title
ES2136673T3 (es) Utilizacion del factor de crecimiento de los queratinocitos para la obtencion de medicamentos.
ATE308545T1 (de) Chlorophyll- und bacteriochlorophyllester, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
CA2346438A1 (en) Utilisation of dialkylfumarates for treating host-versus-graft reactions and auto-immune diseases
BRPI0415752A (pt) métodos, composições e dispositivos para indução de estase em células, tecidos, órgãos e organismos
NO955361L (no) Organiske aerogeler
ES2116986T3 (es) Composiciones de metal-peptidos y metodos cosmeticos para estimular el crecimiento del cabello.
ES2080837T3 (es) Tratamiento de estados y enfermedades.
ECSP105739A (es) Anticuerpos de neutralización contra gdf-8
ATE112684T1 (de) Verwendung von igf-ii zur behandlung von knochenkrankheiten.
ES2073277T3 (es) Sustancias de naturaleza polipeptida utiles en la terapia humana.
TW200635949A (en) Tripeptide and tetrapeptide sulfones
ES2150902T3 (es) Procedimientos para potenciar la cicatrizacion de heridas y la reparacion de tejidos.
PT1124577E (pt) Utilizacao de uma proteina ompa de enterobacteria para o direccionamento especifico para as celulas apresentadoras de antigenios
FI810380L (fi) Fenylpiperazinderivat av 1,3,4-oxadiazolylfenoler deras framstaellning och dessa innehaollande terapeutiska aemnen
WO2023133053A3 (en) Methods and compositions for inducing ferroptosis in vivo
WIRTHS Life sciences laboratories in Spacelab
CO5310552A1 (es) Compuestos para la terapia y el diagnostico de cancer de pulmon y metodos de uso de los mismos
UA28342A (uk) Спосіб одержання біологічно активної речовини для лікування серцевих захворювань
ATE329613T1 (de) Wachstumhormone inhibitoren enthaltende pharmazeutische zubereitungen oder ihre biologisch aktive fragmente zur behandlung von uterinen myomas
MX9708989A (es) Terapia de celulas alogeneicas para el cancer despues del transplante de celulas madre alogeneicas.
AU673835B2 (en) Medicinal composition comprising TCF-II
CO5300456A1 (es) Compuestos y metodos para el tratamiento y diagnostico del cancer de prostata
AR010354A1 (es) Compuestos sustituidos con sulfonamida, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico asi como preparadosfarmaceuticos que los contienen

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 619370

Country of ref document: ES